Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

JPMorgan analyst Chris Schott says Eli Lilly’s Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidanc ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight ...